fda glp-1 compounding warning letters september 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines FDA Sends Warning Letters to

Compounded tirzepatide requires careful storage to maintain its potency

GLP-1 receptor agonists have demonstrated significant weight loss results in clinical trials, with patients losing 15-22% of body weight over 68 weeks

Aims/hypothesis Unimolecular peptides targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) have been shown to improve glycaemic management in both mice and humans

This drug, indicated for glycemic control in patients aged 10 years and above with type 2 diabetes, serves as an adjunct to diet and exercise

This condition carries a global mortality rate of approximately 8% and is characterized by significantly elevated creatine kinase (CK) levels, often rising to five times the normal upper limit or higher